Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventriculartransplantationheartacutefailure
  Phrases that lowered it: indexaimdrugstrialclinical
• Sponsor's past termination rate: 13.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 84 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.9% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 59473 (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 158 (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3) NCT04037397 · started 2019 · scored riskier than 85% of active trials completed
• Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia NCT01097330 · started 2010 · scored riskier than 90% of active trials terminated
• Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation NCT01898221 · started 2013 · scored riskier than 93% of active trials completed
• A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation NCT00668759 · started 2008 · scored riskier than 55% of active trials completed
• Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm NCT02454283 · started 2015 · scored riskier than 78% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.